Slide you, targeting Slide indications. CDXX, broad XX, I’m the on autoantibody – by to direct pathway the of across XX Bing. sorry, On would like towards the multiple your I so of the Thank attention depleting applicability –
indications studies there the clinical for prioritized we coming in many years. While opportunities, are three have
The is myasthenia first one gravis.
We more the a of go I X by gravis, the planning in patients will with coming are generalized slides. bit into in phases Phase a pivotal in little detail myasthenia study and
in of IgGX-related of We to trial initiate mid-year in pivotal in Both patients potentially potentially planning also disease. with PhaseXb a XXXX. are planned are the studies phases these pivotal
have submitted locales process other We are IND in well. as of the and applications trial the filing and clinical
HLA test awaiting sensitized capable with antigens. significantly The our one in We VIBXXXX, LR transplant have reducing to either alone proof-of-concept of whether also these major to trial or in of initiated candidates is titers idea are a who patients kidney of combination antibodies. inebilizumab another highly
that it is targeting – diseases the in It similarities by in pathogenic little myasthenia a XX, has antibody gravis. gravis by damage. Myasthenia is disease junction. about is all more receptors On mediated detail Slide animal. results a are a to tissue part that bit on In that, neuromuscular many both antibodies caused
of junction XX% for of or antigen Approximately against neuromuscular positive receptor specific of approximately receptor specific for case and an muscle antibody muscle the antibodies the patients have are these myasthenia either In at target autoantibodies X% the expressed gravis, the kinase. acetylcholine called kinase. cases acetylcholine
towards the study The to of will we I in gravis. as year. patients. We patients And approximately inebilizumab middle are with will initiate myasthenia – enroll we said, XXX generalized trial plan this on the trial
IgGX-related into by about IgGX-related disease of are common is entity. characterized On a different known Slide fibrosis. variety plasmablast-like These The little a that tissues, ultimately names. #XX, variety causes of more which newly of and is disease subsequent disease. cells previously defined a by these inflammation bit diseases a of relatively they invasion were feature
systems organ organ the system any biliary be the liver, can virtually involved. retroperitoneal, involved tract, Commonly include but the
these IgGX disease. in plasma they in tend diseases the the Another of of are the IgGX the severity common that, levels of by levels to feature correlate with high and is characterized
XX,XXX The people treatment reducing mainstay And glucocorticoids. is very in activity. disease The These there scant, to although current United or in generally data affects believe we approximately are older. of epidemiological the States. XX patients are of these quite is disease years XX,XXX older effective
flare tends and corticosteroid patients reduced. drug recur very with soon treated be can as many a use substantial are However, chronically toxicity. as to to steroids, And the therefore, need doses disease which
the said, to high recurrence at Xb to of disease requiring be The started the of a of trial. treatment, trial recurrence. flares test disease in of ability will disease recently with inebilizumab active prevent middle will year. I risk who planned in We That, patients enroll this as is are Phase
to On there the of for some depicting action With that, other this on move graph candidates. pipeline is of molecule. a mechanism let’s our Slide XX,
CDXX pathways. a biological So ligand. CDXX that VIBXXXX ligand receptor, The ligand three of is molecule pair different in CDXX targets receptor is important
and cells and maturation formation, T cell for T interaction of and CDXX critical ligands occur expressed formation. The these B on center. receptor is center on is expressed germinal germinal One antibody cells at CDXX activated
If occur. this, you cannot centers cannot block germinal and responses antibody form
macrophages CDXX targeting in nephritis, is as activation also the been Early of disease of is important ligand ligand first-generation for CDXX and bowel cell for lupus or macrophages. initial function the results a diseases and and antibodies well dendritic have inflammatory look validated target. such ITP ligand CDXX evaluated activation promising.
these first-generation crosslinking had by mediated crosslinking cells. that a side expressed These involved ligand liability However, effects. significant neighboring thromboembolic platelets gamma receptors CDXX were platelets with molecules on FC – on effects side
that of XX, To engaging human mutated circumvent that CDXX two to comprises gamma recognition this scaffold FC to and engineered Slide convey the molecule on VIBXXXX, depicted domains albumin. of This capable serum ligand are be toxicity, to [ph] a not TnX receptors. is we as
is binding aggregation type studies and clinical very of have that we also gamma any toxicities. predicted FC a of aggregation thromboembolic liability where or this to not saddled in two receptors, it have careful in evidence initial So be would the we not verified therefore the platelet with preclinical of platelet seen capable no molecule be of trials, this
in are rheumatoid left focus Slide some study panel. Xb busy DAS-XX standard on – side panel the your a disease our This multiple of attention results XX activity ascending This slide, from arthritis moderately therapy. score in the active outcome Phase XX, rheumatoid however, patients with depicted. dose On depicts arthritis measure a is
milligrams. is that profound and X,XXX you dose-dependent, and there a in two see doses – especially in in As reduction disease rapid the activity higher X,XXX
the trial of bar of the state that And low a this activity today three-month at three that direct would in order truly attention On disease the the side remission. of of of quarters you is or disease. end second we in panel, row either in third were shows your to to right meet that patients period approximately arthritis structural prevent I progression rheumatoid that the and the to have progression
to treatment a like respect and treatment was maintained, as another also point measures, three have factor effect would patients to saw the both followed biomarkers beyond out out of for to of I variety titers. outcome three-month treatment months you as we as that, period clinical the rheumatoid such well with
pathway a ligand to large be of crucial CDXX number thought autoimmune The is in diseases.
initially, have prioritize well in trial kidney syndrome Sjögren’s as to We as decided a transplant started rejection. smaller
talk whom about for about with medical well after a Sjögren’s Therefore, for treatment treatment maybe second arthritis. syndrome X United that need. no most over of effect the a is Sjögren’s Sjögren’s million rheumatoid currently there’s syndrome common Let’s works. no XXX,XXX there treatment and There’s to eligible thought really, large biologic. first. is disease approved unmet rheumatic patients the It’s out States, in
overexpressed know that inflamed pathway circulation, this are in animal important know the have in tissues models that We with ligand we especially in Sjögren’s and CDXX, syndrome. also ligand important patients And from this is the in We CDXX disease. disease. but that the both receptor this confidence is in
have Sjögren’s We focused with of high patients. activity, patients disease in addition patients. dry who that, trial syndrome, traditionally, symptom approximately trial symptoms. Phase But fatigue activity, XXX also a a left that study on will have the mouth, have And a study we to subjective size, trial, with fairly we high to related patients have burden initiated total substantial Sjögren’s these systemic but systemic will other in a and a disease patients Xb
and months enrolling the the occur shift situation. enrollment caveat COVID-XX we due to these early trial with to over that XX This has approximately may year, next current the timelines started this expect
is transplant The is and and belatacept kidney inhibitors. mainstay have transplant The patients who targeting second rejection. smaller is of of immunosuppressive regimens trial a combination prevent current regimen rejection effective. calcineurin study, transplant order proof-of-concept received kidney This need to in quite a
slow a recent trial be is associated but this test transplant deterioration inhibitors objective renal and XXXX in combination the function, less belatacept kidney to is a effective in can toxicity. kidney undesirable transplant. kidney The with of However, calcineurin are highly with toxicity, resulting obviously associated which patients preventing with in that hypothesis rejection, of of as
Finally, targets XX, of a This amount and I interferons, cells, or expressed would TNF, Plasmacytoid that role talk is pDCs, monoclonal like very VIBXXXX. but about that They produce dendritic briefly cytokines, the other antigen Slide plasmacytoid surface X specifically particularly on IL-XX, play in multifaceted to a of cells. an on large is antibody type also dendritic inflammation. a IL-X cytokines.
cells, are cells They dangerous cells such activate recognize are tissues as cytokines, also others. signals they immune as cells. such These important that T macrophages. ensue recognize in be signals, acids, to cells. in as activating produce then nucleic attics to in as well – complex amounts data do thought circulation other when viral the and as neutrophils and these of these immunological other large immune And [ph]
in state patients maintaining in tissues are these be However, autoimmune proinflammatory with cells very thought in important also to a diseases.
skin a of pDCs enrichment skin these see lesions. tremendous patients with take you if of disease, you example, lupus can For in biopsies
Similarly, biopsies interrupt numbers therefore, is in autoimmune These disease, with muscle myositis depleting proinflammatory patients of can and a and And to these produce inflammation have are been pDCs analyzed. these thought when have been as of lot cells found they also cycle. this that cytokines hypothesis the large maintain in diseases. such
Phase dose as The our in disease. three on Xb conducting with of trial depicted lupus cohorts skin patients process enrolled. the in schematic, XX, currently are We multiple were Slide ascending trial
diseases, Sjögren’s, cohort including with polymyositis as The mix as well were eight dermatomyositis. lupus, different a systemic autoimmune patients first of and sclerosis, cutaneous
to recently patients Cohort – X pDCs demonstrated patient XX VIBXXXX, recently depletes last X XX X Xa that the idea comprises was already have Phase cutaneous this circulation, in we patients. of trial, our in study inflamed which the enrolled also but The cohort enrolled is test, whether in not have only tissue. just with lupus. that X and only Cohorts and comprises in just we patients
will patients And that that after and inflamed so will from lesions. VIBXXXX skin get disappear they biopsies that end, and cells will demonstrate lupus we actually with receive to these before can cutaneous treatment,
that, index. lupus classic activity In one name addition the to the cutaneous by activity disease of and of secondary is measure skin severity in endpoints a lupus of
And lesions with improve least to signal a we as whether after over so hope at VIBXXXX. to directional these get time treatment will
the analysis cohort include an towards of are expected conduct will cohort that We And the of this end interim for final this the of That X. results in results is are also year. expected X second that quarter year. the
With this, Mitchell Chief Officer. to our I would over turn to Financial like Chan, it
